Melis McHenry
Associate Director Regeneron Pharmaceuticals
Seminars
Thursday 26th March 2026
The Role & Implementation of AAV Immunogenicity Assays in Gene Therapy Clinical Trials
2:50 pm
- Importance of detecting pre-existing AAV antibodies to ensure safety and efficacy in gene therapy trials
- Determination of thresholds for AAV immunogenicity assays through pre-clinical and clinical studies
- Implementation of validated AAV cut-offs in patient selection strategies
